Atopic Dermatitis

Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older

Atopic Dermatitis Recent News

AbbVie Presents New Upadacitinib Data In Atopic Dermatitis
Pfizers' JAK Inhibitor Approved In Japan For Atopic Dermatitis
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD).
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials
VYNE Therapeutics Stock Drops On Potential Sale Of Topical Minocycline Franchise
FDA Will Not Meet Goal Dates For Pfizer's Xeljanz, Abrocitinib Applications
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.
RAPT Therapeutics Stock Soars As Atopic Dermatitis Candidate Shows Promising Action In Early-Stage Study
Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
Cara Therapeutics' Stock Plummets As Korsuva Flunks In Mid-Stage Atopic Dermatitis Study
Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies
Kindred's New IL-31 Antibody Shows Improved Shelf Life In PK Study For Canine Dermatitis
AbbVie's Upadacitinib US Application Review In Atopic Dermatitis Postponed
Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis
Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe ato
Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11
FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease
Expectations For Regeneron No Longer Realistic; Analyst Downgrades
Anacor Shares Surge To All-Time Highs After Phase 3 Trials Of Eczema Drug